In­sid­ers: The top 20 rare dis­ease spe­cial­ists spot­light key biotech trends be­hind the boom

Im­age: Bio­gen CEO Michel Vounatsos at the com­pa­ny’s of­fices in Cam­bridge, MA on Jan. 3, 2017. The Boston Globe via Get­ty

Some of the most in­ter­est­ing on­go­ing dis­cus­sions in biotech are fo­cused on a few key points: how do you cre­ate val­ue, which com­pa­nies are cre­at­ing the great­est val­ue and where is the next Bio­gen or Cel­gene com­ing from?

This piece is for all of you who care to know more about that.

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.